Apos® Study Reveals: 87% of Apos®-Treated Patients With Knee OA Did Not Pursue Further Surgical Treatment at 5 Years
Apos® Study Reveals 87% of Apos® treated patients who suffer from knee osteoarthritis did not need to pursue further surgical treatment at 5 years. AposHealth® is proud to announce the acceptance of a research article in the Journal of Musculoskeletal Research. This study conducted by Montefiore Health System demonstrates a remarkable 87% of patients […]
AposHealth® Honored with Prestigious Innovations Award from PBGH, an organization dedicated to enhancing healthcare quality and affordability for employees
AposHealth®, a global leader in musculoskeletal (MSK) solutions, has been recognized with the award from the Pittsburgh Business Group on Health (PBGH) at the 2023 Fall Innovations Summit.1 PBGH, one of the nation’s foremost non-profit organizations dedicated to enhancing healthcare quality and affordability for employees, bestowed this honor upon AposHealth® for its groundbreaking approach to […]
Apos® Selected as the First Technology Supported by NHS England’s MedTech Funding Mandate for 2024/25
AposHealth® a disruptive global company focused on revolutionising the treatment of musculoskeletal (MSK) conditions such as knee osteoarthritis (OA) is delighted to announce that its flagship solution Apos® has been chosen as the first new technology to receive support under the MedTech Funding Mandate (MTFM) for the coming financial year 2024/25. This important selection by […]
AposHealth®’s Breakthrough Study Shows 89% of Eligible Total Knee Replacement Patients Avoid Surgery for Up to 6 Years with Apos®
AposHealth®, a pioneering healthcare company specializing in innovative non-surgical musculoskeletal interventions, is proud to announce results of a clinical study that demonstrates an impressive 89% of patients eligible for Total Knee Replacement (TKR) surgery were able to avoid it for up to 6 years.1 The study, published in Therapeutic Advances in Musculoskeletal Disease, underscores the […]
The Honorable David Shulkin M.D., Ninth Secretary, US Department of Veteran Affairs, Joins AposHealth® Board
AposHealth®, a pioneering healthcare technology company specializing in innovative solutions for chronic musculoskeletal pain, is pleased to announce the appointment of Dr. David Shulkin as a Board Member. Dr. Shulkin brings a wealth of experience and expertise to the AposHealth team. With a career spanning decades in healthcare leadership and public service including former Secretary […]
New 5-year study reveals low rates of total knee replacement and reduced utilization of healthcare services in patients treated with Apos®
AposHealth was awarded official guidance for the recommended use of its flagship product Apos® by The National Institute for Health and Care Excellence (NICE).
Apos® Demonstrates Long-Term Effectiveness in Avoiding Knee Surgery Providing Additional Evidence to Support Its Innovative Musculoskeletal Program
AposHealth was awarded official guidance for the recommended use of its flagship product Apos® by The National Institute for Health and Care Excellence (NICE).
NICE recommends Apos® for people with knee osteoarthritis
AposHealth was awarded official guidance for the recommended use of its flagship product Apos® by The National Institute for Health and Care Excellence (NICE).
Real-World UK Study Shows Apos® to Delay Knee Replacement Surgery by 2 Years or More
A UK-based study aimed to affirm the rate of surgery avoidance over 2 years among candidates for total knee replacement (TKR) who were treated with Apos®. The study, published in Journal of Orthopaedic Experience and Innovation, is the first on an NHS population demonstrating real-world outcomes within a UK knee pain pathway. Patients with end-stage […]
Apos®, a Non-Invasive Knee Treatment, Proven to Delay Surgery According to a Real-World Study
A recent study on Apos®, a medical device that treats chronic knee conditions, could have significant implications on the cost, pain, and quality-of-life problems associated with knee osteoarthritis (OA). The study data was released by Heritage Provider Network (HPN), a nationally recognized physician network that provides care under financial at-risk contracts with its partner health […]
